
Pubmed-entry ::= {
  pmid 28925793,
  medent {
    em std {
      year 2017,
      month 9,
      day 20,
      hour 6,
      minute 0
    },
    cit {
      title {
        name "Sequential administration of MVA-based vaccines and
 PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth
 and survival: Preclinical studies with MVA-betaGal and MVA-MUC1 (TG4010) in a
 murine tumor model."
      },
      authors {
        names std {
          {
            name ml "Remy-Ziller C",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Thioudellet C",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Hortelano J",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Gantzer M",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Nourtier V",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Claudepierre MC",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Sansas B",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Preville X",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Bendjama K",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Quemeneur E",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          },
          {
            name ml "Rittner K",
            affil str "a Department of Oncoimmunology , Transgene S.A. , Parc
 d'Innovation, Illkirch-Graffenstaden , Cedex , France."
          }
        }
      },
      from journal {
        title {
          iso-jta "Hum Vaccin Immunother",
          ml-jta "Hum Vaccin Immunother",
          issn "2164-554X",
          name "Human vaccines & immunotherapeutics"
        },
        imp {
          date std {
            year 2018,
            month 1,
            day 2
          },
          volume "14",
          issue "1",
          pages "140-145",
          language "eng",
          pubstatus ppublish,
          history {
            {
              pubstatus pubmed,
              date std {
                year 2017,
                month 9,
                day 20,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus medline,
              date std {
                year 2019,
                month 1,
                day 12,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus other,
              date std {
                year 2017,
                month 9,
                day 20,
                hour 6,
                minute 0
              }
            }
          }
        }
      },
      ids {
        pubmed 28925793,
        doi "10.1080/21645515.2017.1373921",
        other {
          db "pmc",
          tag str "PMC5791558"
        },
        other {
          db "ELocationID doi",
          tag str "10.1080/21645515.2017.1373921"
        }
      }
    },
    abstract "TG4010, a Modified Vaccinia virus Ankara (MVA) expressing human
 mucin1 (MUC1) has demonstrated clinical benefit for patients suffering from
 advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy.
 To support its development, preclinical experiments were performed with
 either TG4010 or beta-galactosidase-encoding MVA vector (MVA-betagal) in mice
 presenting tumors in the lung. Tumor growth was obtained after intravenous
 injection of CT26 murine colon cancer cells, engineered to express either
 MUC1 or betagal. Mice showed increased survival rates after repeated
 intravenous injections of TG4010 or MVA-betagal, compared to an empty MVA
 control vector. Treatment with MVA vectors led to the accumulation of
 CD3(dim)CD8(dim) T cells, with two subpopulations characterized as
 KLRG1(+)CD127(-) short-lived effector cells (SLECs), and KLRG1(-)CD127(-)
 early effector cells (EECs) comprising cells releasing IFNgamma, Granzyme B
 and CD107a upon antigen-specific peptide stimulation. EECs were characterized
 by an up-regulation of PD-1. Tumor growth in the diseased lung correlated
 with the appearance of PD1(+) Treg cells that partially disappeared after
 TG4010 treatment. At late stage of tumor development in the lung, PD-L1 was
 detected on CD45(-) tumor cells, on CD4(+) cells, including Treg cells, on
 CD3(+)CD8(+) and CD3(dim)CD8(dim) T lymphocytes, on NK cells, on MDSCs and on
 alveolar macrophages. We demonstrated that targeting the PD-1/PD-L1 pathway
 with blocking monoclonal antibodies several days after TG4010 treatment, at
 late stage of tumor development, enhanced the therapeutic protection induced
 by the vaccine, supporting the ongoing clinical evaluation of TG4010
 immunotherapy in combination with Nivolumab.",
    mesh {
      {
        term "Animals"
      },
      {
        term "Antineoplastic Agents, Immunological",
        qual {
          {
            mp TRUE,
            subh "administration & dosage"
          }
        }
      },
      {
        term "B7-H1 Antigen",
        qual {
          {
            subh "immunology"
          },
          {
            subh "metabolism"
          }
        }
      },
      {
        term "Cancer Vaccines",
        qual {
          {
            mp TRUE,
            subh "administration & dosage"
          }
        }
      },
      {
        term "Carcinoma, Non-Small-Cell Lung",
        qual {
          {
            subh "immunology"
          },
          {
            subh "mortality"
          },
          {
            mp TRUE,
            subh "therapy"
          }
        }
      },
      {
        term "Cell Line, Tumor"
      },
      {
        term "Combined Modality Therapy",
        qual {
          {
            subh "methods"
          }
        }
      },
      {
        term "Immunotherapy",
        qual {
          {
            mp TRUE,
            subh "methods"
          }
        }
      },
      {
        term "Injections, Intravenous"
      },
      {
        term "Membrane Glycoproteins",
        qual {
          {
            mp TRUE,
            subh "administration & dosage"
          }
        }
      },
      {
        term "Mice"
      },
      {
        term "Mice, Inbred BALB C"
      },
      {
        term "Mucin-1",
        qual {
          {
            subh "immunology"
          }
        }
      },
      {
        term "Nivolumab",
        qual {
          {
            subh "administration & dosage"
          }
        }
      },
      {
        term "Programmed Cell Death 1 Receptor",
        qual {
          {
            mp TRUE,
            subh "antagonists & inhibitors"
          },
          {
            subh "immunology"
          },
          {
            subh "metabolism"
          }
        }
      },
      {
        term "Treatment Outcome"
      },
      {
        term "Vaccinia virus",
        qual {
          {
            mp TRUE,
            subh "immunology"
          }
        }
      },
      {
        term "Xenograft Model Antitumor Assays"
      }
    },
    substance {
      {
        type nameonly,
        name "Antineoplastic Agents, Immunological"
      },
      {
        type nameonly,
        name "B7-H1 Antigen"
      },
      {
        type nameonly,
        name "Cancer Vaccines"
      },
      {
        type nameonly,
        name "MUC1 protein, human"
      },
      {
        type nameonly,
        name "Membrane Glycoproteins"
      },
      {
        type nameonly,
        name "Mucin-1"
      },
      {
        type nameonly,
        name "Programmed Cell Death 1 Receptor"
      },
      {
        type nameonly,
        name "TG4010"
      },
      {
        type cas,
        cit "31YO63LBSN",
        name "Nivolumab"
      }
    },
    pmid 28925793,
    pub-type {
      "Journal Article"
    },
    status medline
  }
}


